Worth reading
35Immaterial
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Agreements reached under this partnership
Sales partnership agreement4521KAKEN PHARMACEUTICAL CO.,LTD.
Alliance partnerDaito Pharmaceutical Co.,Ltd.
Details of the alliance
- 1
Sales partnership in Japan
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
Business DescriptionA pharmaceutical company that globally conducts integrated research and development through manufacturing, with active pharmaceutical ingredients and drug products as its 2 core businesses. It manufactures and sells active pharmaceutical ingredients and drug products for prescription and over-the-counter medicines.
LocationToyama City, Toyama Prefecture
Alliance start dateThe timing of Kaken Pharmaceutical's sales launch will be determined after discussions with Daito.
| Item | Details |
|---|---|
| Name of alliance partner | Daito Pharmaceutical Co.,Ltd. |
| Alliance partner's business activities | A pharmaceutical company that globally conducts integrated research and development through manufacturing, with active pharmaceutical ingredients and drug products as its 2 core businesses. It manufactures and sells active pharmaceutical ingredients and drug products for prescription and over-the-counter medicines. |
| Alliance partner's location | Toyama City, Toyama Prefecture |
| Type of alliance | Sales partnership agreement |
| Details of the alliance | Sales partnership in Japan |
| Alliance start date | The timing of Kaken Pharmaceutical's sales launch will be determined after discussions with Daito. |
Items this document does not state (17)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateShare Acquisition Date and Payment DateImpact on Business PerformanceChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The products are highly compatible with Kaken Pharmaceutical's existing products and are well suited to the value proposition pursued by its Satisfaction Project. The company aims to generate synergies with its existing products, enhance its presence in therapeutic areas where it has particular strengths, and contribute to extending healthy life expectancy.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.